Beyond Tumor Borders: Intratumoral Microbiome Effects on Tumor Behavior and Therapeutic Responses

키워드

참고문헌 (144)

1. De Sousa E Melo F, "Cancer heterogeneity--a multifaceted view", EMBO Rep, 14, pp.686~695 (2013)
2. Allison KH, "Heterogeneity and cancer", Oncology(Williston Park), 28, pp.772~778 (2014)
3. Inamura K, "Roles of microbiota in response to cancer immunotherapy", Semin Cancer Biol, 65, pp.164~175 (2020)
4. Nejman D, "The human tumor microbiome is composed of tumor type-specific intracellular bacteria", Science, 368, pp.973~980 (2020)
5. Heymann CJF, "The intratumoral microbiome : characterization methods and functional impact", Cancer Lett, 522, pp.63~79 (2021)
6. Wei MQ, "Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours", Eur J Cancer, 43, pp.490~496 (2007)
7. Al-Mariri A, "Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen", Infect Immun, 70, pp.1915~1923 (2002)
8. Kasinskas RW, "Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro", Biotechnol Bioeng, 94, pp.710~721 (2006)
9. Bermudes D, "Tumor-targeted Salmonella. Highly selective delivery vectors", Adv Exp Med Biol, 465, pp.57~63 (2000)
10. Wen Y, "Association between oral microbiota and human brain glioma grade : a case-control study", Front Microbiol, 12, pp.746568~ (2021)
11. Fan X, "Human oral microbiome and prospective risk for pancreatic cancer : a population-based nested case-control study", Gut, 67, pp.120~127 (2018)
12. Jeong JY, "Diversity in the extracellular vesicle-derived microbiome of tissues according to tumor progression in pancreatic cancer", Cancers(Basel), 12, pp.2346~ (2020)
13. Fan Y, "Gut microbiome alterations affect glioma development and Foxp3 expression in tumor microenvironment in mice", Front Oncol, 12, pp.836953~ (2022)
14. Khan AA, "Normal to cancer microbiome transformation and its implication in cancer diagnosis", Biochim Biophys Acta, 1826, pp.331~337 (2012)
15. Yang L, "Intratumoral microbiota : roles in cancer initiation, development and therapeutic efficacy", Signal Transduct Target Ther, 8, pp.35~ (2023)
16. Wong-Rolle A, "Unexpected guests in the tumor microenvironment : microbiome in cancer", Protein Cell, 12, pp.426~435 (2021)
17. González-Sánchez P, "The microbiome(s)and cancer : know thy neighbor(s)", J Pathol, 254, pp.332~343 (2021)
18. Barrett M, "Mutagenesis by microbe : the role of the microbiota in shaping the cancer genome", Trends Cancer, 6, pp.277~287 (2020)
19. Chagneau CV, "The pks island: a bacterial Swiss army knife? Colibactin: beyond DNA damage and cancer", Trends Microbiol, 30, pp.1146~1159 (2022)
20. Jinadasa RN, "Cytolethal distending toxin : a conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian cell lineages", Microbiology, 157, pp.1851~1875 (2011)
21. Lara-Tejero M, "CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity", Infect Immun, 69, pp.4358~4365 (2001)
22. Fedor Y, "From single-strand breaks to double-strand breaks during S-phase : a new mode of action of the Escherichia coli Cytolethal Distending Toxin", Cell Microbiol, 15, pp.1~15 (2013)
23. Guerra L, "Do bacterial genotoxins contribute to chronic inflammation, genomic instability and tumor progression?", FEBS J, 278, pp.4577~4588 (2011)
24. Mizumoto A, "Molecular mechanisms of acetaldehyde-mediated carcinogenesis in squamous epithelium", Int J Mol Sci, 18, pp.1943~ (2017)
25. Liu Y, "Bacterial genotoxin accelerates transient infection-driven murine colon tumorigenesis", Cancer Discov, 12, pp.236~249 (2022)
26. Apopa PL, "PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin", Front Microbiol, 9, pp.1757~ (2018)
27. Zhang L, "The role of the microscopic world : exploring the role and potential of intratumoral microbiota in cancer immunotherapy", Medicine(Baltimore), 103, pp.e38078~ (2024)
28. La Rosa GR, "Association of oral dysbiosis with oral cancer development", Oncol Lett, 19, pp.3045~3058 (2020)
29. Goodwin AC, "Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis", Proc Natl Acad Sci U S A, 108, pp.15354~15359 (2011)
30. Wang X, "4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages", Gastroenterology, 142, pp.543~551 (2012)
31. Payne CM, "Deoxycholate induces mitochondrial oxidative stress and activates NF-κB through multiple mechanisms in HCT-116 colon epithelial cells", Carcinogenesis, 28, pp.215~222 (2007)
32. Song P, "Wnt", β-catenin signaling pathway in carcinogenesis and cancer therapy, 2024, pp.17, 46~
33. Buti L, "Helicobacter pylori cytotoxin-associated gene A(CagA)subverts the apoptosis-stimulating protein of p53(ASPP2)tumor suppressor pathway of the host", Proc Natl Acad Sci U S A, 108, pp.9238~9243 (2011)
34. Rubinstein MR, "Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin", β-catenin signaling via its FadA adhesin, 2013, pp.14, 195~206
35. Lu R, "Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway", Oncogenesis, 3, pp.e105~ (2014)
36. Wu S, "Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage", J Cell Sci, 120, pp.1944~1952 (2007)
37. Wu S, "Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation", Gastroenterology, 124, pp.392~400 (2003)
38. Fan JY, "Bacteria in cancer therapy : A new generation of weapons", Cancer Med, 11, pp.4457~4468 (2022)
39. Boesch M, "Tumour neoantigen mimicry by microbial species in cancer immunotherapy", Br J Cancer, 125, pp.313~323 (2021)
40. Overacre-Delgoffe AE, "Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer", Immunity, 54, pp.2812~2824 (2021)
41. Rizvi ZA, "High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity", Sci Adv, 7, pp.eabg5016~ (2021)
42. Host KM, "Kaposi’s sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes", mBio, 8, pp.e00917-17~ (2017)
43. Leinwand JC, "Intrahepatic microbes govern liver immunity by programming NKT cells", J Clin Invest, 132, pp.e151725~ (2022)
44. Wang H, "The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer", Cell Metab, 34, pp.581~594 (2022)
45. Kim OY, "Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response", Nat Commun, 8, pp.626~ (2017)
46. Singh N, "Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis", Immunity, 40, pp.128~139 (2014)
47. Sepich-Poore GD, "The microbiome and human cancer", Science, 371, pp.eabc4552~ (2021)
48. Pratap Singh R, "Intratumoral microbiota changes with tumor stage and influences the immune signature of oral squamous cell carcinoma", Microbiol Spectr, 11, pp.e0459622~ (2023)
49. Triner D, "Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice", Gastroenterology, 156, pp.1467~1482 (2019)
50. Alam A, "Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer", Cancer Cell, 40, pp.153~167 (2022)
51. Ma J, "Influence of intratumor microbiome on clinical outcome and immune processes in prostate cancer", Cancer(Basel), 12, pp.2524~ (2020)
52. Le Noci V, "Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy : a strategy to promote immunosurveillance against lung metastases", Cell Rep, 24, pp.3528~3538 (2018)
53. Liu NN, "The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells", Cancer Cell, 41, pp.1927~1944 (2023)
54. Gur C, "Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack", Immunity, 42, pp.344~355 (2015)
55. Gur C, "Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1", OncoImmunology, 8, pp.e1581531~ (2019)
56. Toker J, "The microbiome in immuno-oncology", Adv Exp Med Biol, 1244, pp.325~334 (2020)
57. Wang R, "Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate", Nat Commun, 13, pp.2522~ (2022)
58. Zhang Y, "Advancements in the impact of human microbiota and probiotics on leukemia", Front Microbiol, 15, pp.1423838~ (2024)
59. Rowe M, "Epstein-Barr virus and Burkitt lymphoma", Chin J Cancer, 33, pp.609~619 (2014)
60. Giam CZ, "HTLV-1 infection and adult T-cell leukemia", lymphoma-a tale of two proteins : Tax and HBZ, 2016, pp.8, 161~
61. Fischer S, "Human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients", Leuk Res Rep, 3, pp.70~72 (2014)
62. Nomura M, "Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors", JAMA Netw Open, 3, pp.e202895~ (2020)
63. Devoy C, "Understanding and harnessing triple-negative breast cancer-related microbiota in oncology", Front Oncol, 12, pp.1020121~ (2022)
64. Lavoie S, "Expression of free fatty acid receptor 2 by dendritic cells prevents their expression of interleukin 27 and is required for maintenance of mucosal barrier and immune response against colorectal tumors in mice", Gastroenterology, 158, pp.1359~1372 (2020)
65. Dupraz L, "Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal γδ T cells", Cell Reports, 36, pp.109332~ (2021)
66. He Y, "Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity", Cell Metab, 33, pp.988~1000 (2021)
67. Goto T, "Microbiota and lung cancer", Semin Cancer Biol, 86, pp.1~10 (2022)
68. Bailón E, "Butyrate in vitro immune-modulatory effects might be mediated through a proliferation-related induction of apoptosis", Immunobiology, 215, pp.863~873 (2010)
69. Pandya G, "A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma", Semin Cancer Biol, 86, pp.682~692 (2022)
70. Yang Q, "A review of gut microbiota-derived metabolites in tumor progression and cancer therapy", Adv Sci(Weinh), 10, pp.e2207366~ (2023)
71. Mikó E, "Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness", Biochim Biophys Acta Bioenerg, 1859, pp.958~974 (2018)
72. Sinha SR, "Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation", Cell Host Microbe, 27, pp.659~670 (2020)
73. Farhana L, "Bile acid : a potential inducer of colon cancer stem cells", Stem Cell Res Ther, 7, pp.181~ (2016)
74. Rossi T, "Microbiota-derived metabolites in tumor progression and metastasis", Int J Mol Sci, 21, pp.5786~ (2020)
75. Nguyen TT, "Lithocholic acid stimulates IL-8 expression in human colorectal cancer cells via activation of Erk1", 2 MAPK and suppression of STAT3 activity, 2017, pp.118, 2958~2967
76. Lin R, "Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation", Oncogene, 39, pp.4983~5000 (2020)
77. Jin C, "Commensal microbiota promote lung cancer development via γδ T cells", Cell, 176, pp.998~1013 (2019)
78. Chang CM, "Intratumoral microbiota : unraveling their oncogenic impact on cancer progression with focus on breast cancer therapeutic outcomes", Anticancer Res, 44, pp.2271~2285 (2024)
79. Zhao L, "LPS-induced epithelial-mesenchymal transition of intrahepatic biliary epithelial cells", J Surg Res, 171, pp.819~825 (2011)
80. Kurago ZB, "Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation", Head Neck Pathol, 2, pp.1~12 (2008)
81. Wu X, "Lipopolysaccharide promotes metastasis via acceleration of glycolysis by the nuclear factor-κB", snail, Cancer Metab, pp.2021, 9[DOI]
82. Peng Z, "Lipopolysaccharide exacerbates to the migration, invasion, and epithelial-mesenchymal transition of esophageal cancer cells by TLR4", NF-κB axis, 2023, pp.38, 1090~1099
83. Mager LF, "Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy", Science, 369, pp.1481~1489 (2020)
84. Zhang L, "Inhibition of UBA6 by inosine augments tumour immunogenicity and responses", Nat Commun, 13, pp.5413~ (2022)
85. Hezaveh K, "Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity", Immunity, 55, pp.324~340 (2022)
86. Chakladar J, "The pancreatic microbiome is associated with carcinogenesis and worse prognosis in males and smokers", Cancers(Basel), 12, pp.2672~ (2020)
87. An Y, "The intratumoural microbiota in cancer : new insights from inside", Biochim Biophys Acta Rev Cancer, 1876, pp.188626~ (2021)
88. Walker SP, "Sequence-based characterization of intratumoral bacteria-a guide to best practice", Front Oncol, 10, pp.179~ (2020)
89. Geller LT, "Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine", Science, 357, pp.1156~1160 (2017)
90. Lehouritis P, "Local bacteria affect the efficacy of chemotherapeutic drugs", Sci Rep, 5, pp.14554~ (2015)
91. Jiang Z, "Intratumoral microbiota : a new force in diagnosing and treating pancreatic cancer", Cancer Lett, 554, pp.216031~ (2023)
92. Boulhen C, "TMIGD2 as a potential therapeutic target in glioma patients", Front Immunol, 14, pp.1173518~ (2023)
93. Ghouzlani A, "The promising IgSF11 immune checkpoint is highly expressed in advanced human gliomas and associates to poor prognosis", Front Oncol, 10, pp.608609~ (2021)
94. Farkona S, "Cancer immunotherapy : the beginning of the end of cancer?", BMC Med, 14, pp.73~ (2016)
95. Ghouzlani A, "The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis", Sci Rep, 11, pp.21504~ (2021)
96. Miftah H, "NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma", Front Immunol, 14, pp.1139268~ (2023)
98. Rafii S, "A2AR as a prognostic marker and a potential immunotherapy target in human glioma", Int J Mol Sci, 24, pp.6688~ (2023)
99. Kone AS, "High expression of BTN3A1 is associated with clinical and immunological characteristics and predicts a poor prognosis in advanced human gliomas", Front Immunol, 15, pp.1397486~ (2024)
100. Panda A, "Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer", J Natl Cancer Inst, 110, pp.316~320 (2018)
101. Shi Y, "Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling", J Exp Med, 217, pp.e20192282~ (2020)
102. Anker JF, "Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy", Nat Commun, 9, pp.1591~ (2018)
103. Vétizou M, "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", Science, 350, pp.1079~1084 (2015)
104. Wang X, "Anti-proliferation of breast cancer cells with itraconazole : Hedgehog pathway inhibition induces apoptosis and autophagic cell death", Cancer Lett, 385, pp.128~136 (2017)
105. Ribas A, "Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy", Cell, 170, pp.1109~1119 (2017)
106. Wu H, "Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma", Cancer Res, 83, pp.3131~3144 (2023)
107. Routy B, "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", Science, 359, pp.91~97 (2018)
108. Matson V, "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
109. Zhu S, "Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment", Front Immunol, 13, pp.1074477~ (2022)
110. Jiang SN, "Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy", Mol Ther, 18, pp.635~642 (2010)
111. Yoon WS, "Salmonella typhimurium with γ-radiation induced H2AX phosphorylation and apoptosis in melanoma", Biosci Biotechnol Biochem, 78, pp.1082~1085 (2014)
112. Liu J, "Radiotherapy and the gut microbiome : facts and fiction", Radiat Oncol, 16, pp.9~ (2021)
113. Tonneau M, "The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications : a systematic review", Radiother Oncol, 156, pp.1~9 (2021)
114. Zagury-Orly I, "The effect of radiation and chemoradiation therapy on the head and neck mucosal microbiome : a review", Front Oncol, 11, pp.784457~ (2021)
115. Li Z, "New insights into the relationship between gut microbiota and radiotherapy for cancer", Nutrients, 15, pp.48~ (2022)
116. El Alam MB, "A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers", PLoS One, 16, pp.e0247905~ (2021)
117. Oliva M, "Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy(ROMA LA-OPSCC study)", Br J Cancer, 124, pp.1543~1551 (2021)
118. Jiang C, "A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma", Cancer, 125, pp.1081~1090 (2019)
119. Dong J, "Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models", Cell Reports, 37, pp.109886~ (2021)
120. Kwon SY, "Exploiting bacteria for cancer immunotherapy", Nat Rev Clin Oncol, 21, pp.569~589 (2024)
121. Aganja RP, "Salmonella as a promising curative tool against cancer", Pharmaceutics, 14, pp.2100~ (2022)
122. Badie F, "Use of Salmonella bacteria in cancer therapy : direct, drug delivery and combination approaches", Front Oncol, 11, pp.624759~ (2021)
123. Theys J, "Clostridium to treat cancer : dream or reality?", Ann Transl Med, 3, pp.S21~ (2015)
124. Wall DM, "Targeting tumors with Salmonella typhimurium-potential for therapy", Oncotarget, 1, pp.721~728 (2010)
125. Canale FP, "Metabolic modulation of tumours with engineered bacteria for immunotherapy", Nature, 598, pp.662~666 (2021)
126. Singh M, "Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy", Br J Cancer, 111, pp.1945~1954 (2014)
127. Zheng JH, "Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin", Sci Transl Med, 9, pp.eaak9537~ (2017)
128. Su M, "Role of the crosstalk between autophagy and apoptosis in cancer", J Oncol, 2013, pp.102735~ (2013)
129. Wang Y, "Crosstalk between autophagy and microbiota in cancer progression", Mol Cancer, 20, pp.163~ (2021)
130. Liu B, "Blockage of autophagy pathway enhances Salmonella tumor-targeting", Oncotarget, 7, pp.22873~22882 (2016)
131. Loeffler M, "Inhibition of tumor growth using salmonella expressing Fas ligand", J Natl Cancer Inst, 100, pp.1113~1116 (2008)
132. Chen J, "Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model", Cancer Sci, 103, pp.325~333 (2012)
133. Chen J, "Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy", Biomed Pharmacother, 145, pp.112443~ (2022)
134. Lee CH, "Salmonella induce autophagy in melanoma by the downregulation of AKT", mTOR pathway, 2014, pp.21, 309~316
135. Alizadeh S, "Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax", Bcl-xL and AKT, Iran J Basic Med Sci, pp.2020, 23[DOI]
136. Bettegowda C, "The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT", Nat Biotechnol, 24, pp.1573~1580 (2006)
137. Labani-Motlagh A, "The tumor microenvironment : a milieu hindering and obstructing antitumor immune responses", Front Immunol, 11, pp.940~ (2020)
138. Lin Q, "IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella", Nat Commun, 12, pp.2537~ (2021)
139. Chandra D, "Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice", Br J Cancer, 108, pp.2281~2290 (2013)
140. Weibel S, "Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment", Cell Microbiol, 10, pp.1235~1248 (2008)
141. Zhang X, "The biology and function of extracellular vesicles in cancer development", Front Cell Dev Biol, 9, pp.777441~ (2021)
142. Frydrychowicz M, "Exosomes-structure, biogenesis and biological role in non-small-cell lung cancer", Scand J Immunol, 81, pp.2~10 (2015)
143. Guo S, "Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246", 92b-3p, Gut, pp.2020[DOI]
144. Fu A, "Emerging roles of intratumor microbiota in cancer metastasis", Trends Cell Biol, 33, pp.583~593 (2023)

관련 논문AI추천